Their top candidate, [68Ga]Ga-P137, which showed a higher tumor uptake than [68Ga]Ga-PSMA-617 (6.43±0.98 vs 3.41±1.31 %ID/g at 1 h post-injection) in the preclinical tumor model was further evaluated in 3 prostate cancer patients and compared head-to-head with [68Ga]Ga-PSMA-617 21. This evidence concerns the gene FOLH1 and prostate carcinoma.